tetano
Editor, Senior Moderator
Br J Haematol
. 2023 Jun 22.
doi: 10.1111/bjh.18932. Online ahead of print. Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration
Yohei Funakoshi[SUP] 1 [/SUP], Kimikazu Yakushijin[SUP] 1 [/SUP], Goh Ohji[SUP] 2 [/SUP], Takaji Matsutani[SUP] 3 [/SUP], Wataru Hojo[SUP] 4 [/SUP], Hironori Sakai[SUP] 4 [/SUP], Sakuya Matsumoto[SUP] 1 [/SUP], Marika Watanabe[SUP] 1 [/SUP], Akihito Kitao[SUP] 1 [/SUP], Yasuyuki Saito[SUP] 5 [/SUP], Shinichiro Kawamoto[SUP] 6 [/SUP], Katsuya Yamamoto[SUP] 1 [/SUP], Taiji Koyama[SUP] 1 [/SUP], Yoshiaki Nagatani[SUP] 1 [/SUP], Shiro Kimbara[SUP] 1 [/SUP], Yoshinori Imamura[SUP] 1 [/SUP], Naomi Kiyota[SUP] 1 7 [/SUP], Mitsuhiro Ito[SUP] 8 [/SUP], Hironobu Minami[SUP] 1 7 [/SUP]
Affiliations
The use of anti-SARS-CoV-2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti-spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV-AbDab clearly demonstrated the response to mRNA SARS-CoV-2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation.
Keywords: B-cell receptor repertoire; haematopoietic stem cell transplantation; mRNA SARS-CoV-2 vaccination; tixagevimab/cilgavimab.
. 2023 Jun 22.
doi: 10.1111/bjh.18932. Online ahead of print. Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration
Yohei Funakoshi[SUP] 1 [/SUP], Kimikazu Yakushijin[SUP] 1 [/SUP], Goh Ohji[SUP] 2 [/SUP], Takaji Matsutani[SUP] 3 [/SUP], Wataru Hojo[SUP] 4 [/SUP], Hironori Sakai[SUP] 4 [/SUP], Sakuya Matsumoto[SUP] 1 [/SUP], Marika Watanabe[SUP] 1 [/SUP], Akihito Kitao[SUP] 1 [/SUP], Yasuyuki Saito[SUP] 5 [/SUP], Shinichiro Kawamoto[SUP] 6 [/SUP], Katsuya Yamamoto[SUP] 1 [/SUP], Taiji Koyama[SUP] 1 [/SUP], Yoshiaki Nagatani[SUP] 1 [/SUP], Shiro Kimbara[SUP] 1 [/SUP], Yoshinori Imamura[SUP] 1 [/SUP], Naomi Kiyota[SUP] 1 7 [/SUP], Mitsuhiro Ito[SUP] 8 [/SUP], Hironobu Minami[SUP] 1 7 [/SUP]
Affiliations
- PMID: 37349876
- DOI: 10.1111/bjh.18932
The use of anti-SARS-CoV-2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti-spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV-AbDab clearly demonstrated the response to mRNA SARS-CoV-2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation.
Keywords: B-cell receptor repertoire; haematopoietic stem cell transplantation; mRNA SARS-CoV-2 vaccination; tixagevimab/cilgavimab.